STOCK TITAN

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Immunome Inc. common stock. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the class, based on 113,250,394 shares outstanding as of May 7, 2026.

The Reporting Persons have shared voting and dispositive power over all 4,832,279 shares and no sole voting or dispositive power. Sirenia is a Delaware limited partnership, and Mr. Silverstein is a U.S. citizen. This amended Schedule 13G reflects ownership of 5% or less of Immunome’s outstanding common stock.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 4,832,279 shares Common stock of Immunome Inc. beneficially owned by the Reporting Persons
Ownership percentage 4.3% Percent of Immunome common stock class held by the Reporting Persons
Shares outstanding 113,250,394 shares Immunome common shares outstanding as of May 7, 2026
Shared voting power 4,832,279 shares Shares over which the Reporting Persons share voting power
Shared dispositive power 4,832,279 shares Shares over which the Reporting Persons share dispositive power
beneficial owner financial
"the beneficial owner of the securities reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power financial
"Shared Voting Power 4,832,279.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 4,832,279.00"
Schedule 13G regulatory
"This amended Schedule 13G reflects ownership"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
percent of class financial
"Percent of class: 4.3%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What stake in Immunome Inc. (IMNM) does Sirenia Capital report?

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 4,832,279 shares of Immunome common stock, representing 4.3% of the outstanding class based on 113,250,394 shares outstanding as of May 7, 2026.

How much voting power over Immunome (IMNM) shares does Sirenia Capital have?

The Reporting Persons have shared voting power over 4,832,279 shares of Immunome common stock and no sole voting power. They also share dispositive power over the same number of shares, indicating joint control over voting and disposition.

Who are the Reporting Persons in this Immunome (IMNM) Schedule 13G/A?

The Reporting Persons are Sirenia Capital Management LP and Alex Silverstein. Sirenia manages investment funds and an account holding Immunome shares, and Mr. Silverstein is the managing member of Sirenia’s general partner. Both disclaim admission of beneficial ownership status.

What is the total number of Immunome (IMNM) shares outstanding used in this filing?

The ownership percentage is calculated using 113,250,394 shares of Immunome common stock outstanding as of May 7, 2026, as reported in Immunome’s Quarterly Report for the quarter ended March 31, 2026.

Does Sirenia Capital own more than 5% of Immunome (IMNM)?

No. The Reporting Persons state beneficial ownership of 4.3% of Immunome’s common stock. The filing notes ownership of 5 percent or less of the class, indicating their stake is below the 5% threshold.

What type of power over Immunome (IMNM) shares do Sirenia and Alex Silverstein hold?

They report 0 shares with sole voting or dispositive power and 4,832,279 shares with shared voting and shared dispositive power. This means voting and disposition decisions are made jointly for these shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





45257U108

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Sirenia Capital Management LP
Signature:/s/ Kolby Loft
Name/Title:Kolby Loft, General Counsel & Chief Compliance Officer
Date:08/14/2026
Alex Silverstein
Signature:/s/ Alex Silverstein
Name/Title:Alex Silverstein, individually
Date:08/14/2026